ArticleERJ open research2025
Pectoral muscle area derived from chest computed tomography to identify quadriceps muscle weakness in COPD.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CT-Derived Pectoralis Muscle Measurements and All-Cause Mortality in COPD.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In patients with COPD, reduced quadriceps strength is associated with poor prognosis. Measuring quadriceps strength requires specific equipment and expertise, which limits its dissemination. Chest computed tomography (CT) scans are routinely performed in COPD patients. It was hypothesised that pectoral muscle area (PMA) derived from chest CT scans was related to quadriceps strength, and that low quadriceps strength could be derived from PMA in stable COPD patients. Methods: In a retrospective cross-sectional study, thoracic CT scans and quadriceps strength were obtained simultaneously. The highest quadriceps strength value of the dominant leg was recorded (in kg). The PMA (sum of right and left measurements, in cm Results: A total of 82 outpatients with stable COPD of varying levels of severity were analysed. The unadjusted r Conclusions: PMA is a reliable surrogate for quadriceps strength assessment in routine COPD management. This easily accessible imaging biomarker could be used to identify COPD patients with low quadriceps strength, not only for prognostic purposes but also to enable them to benefit from interventions aimed at improving muscle weakness.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.